Clovis Oncology (NASDAQ:CLVS) Short Interest Up 14.4% in September
Clovis Oncology (NASDAQ:CLVS) Short Interest Up 14.4% in September
Clovis Oncology (NASDAQ:CLVS – Get Rating) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 33,160,000 shares, an increase of 14.4% from the August 31st total of 28,990,000 shares. Based on an average trading volume of 8,440,000 shares, the days-to-cover ratio is currently 3.9 days.
克洛维斯肿瘤学公司(纳斯达克代码:CLVS-GET评级)是9月份空头股数销量大幅增长的接受者。截至9月15日,空头股数共有3316万股,比8月31日的2899万股增加了14.4%。以平均成交量8,440,000股计算,目前天数与回补比率为3.9天。
Clovis Oncology Price Performance
Clovis肿瘤学价格表现
Shares of NASDAQ:CLVS traded down $0.01 during midday trading on Monday, reaching $1.19. 76,310 shares of the company were exchanged, compared to its average volume of 9,633,150. The business's fifty day moving average is $1.34 and its two-hundred day moving average is $1.53. Clovis Oncology has a one year low of $0.58 and a one year high of $4.76.
纳斯达克:CLVS的股价周一午盘下跌0.01美元,至1.19美元。该公司成交量为76,310股,而其平均成交量为9,633,150股。该业务的50日移动均线切入位在1.34美元,200日移动均线切入位在1.53美元。Clovis Oncology的一年低点为0.58美元,一年高位为4.76美元。
Clovis Oncology (NASDAQ:CLVS – Get Rating) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.09). During the same quarter last year, the company posted ($0.61) EPS. As a group, sell-side analysts expect that Clovis Oncology will post -1.74 earnings per share for the current fiscal year.
克洛维斯肿瘤公司(纳斯达克代码:CLVS-GET Rating)最近一次发布季度收益数据是在8月8日星期一。这家生物制药公司公布了该季度每股收益(0.50美元),低于普遍预期的(0.41美元)和(0.09美元)。去年同期,该公司公布的每股收益为0.61美元。卖方分析师预计,Clovis Oncology本财年的每股收益将达到1.74美元。
Institutional Inflows and Outflows
机构资金流入和流出
Clovis Oncology Company Profile
Clovis肿瘤学公司简介
(Get Rating)
(获取评级)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Clovis Oncology,Inc.是一家生物制药公司,专注于在美国、欧洲和国际上收购、开发抗癌药物并将其商业化。其商业产品包括Rubra(Rucaparib)片剂,这是一种小分子聚ADP-核糖聚合酶抑制剂,用于单一疗法治疗与恶性BRCA突变相关的晚期卵巢癌患者,这些患者已接受两种或两种以上化疗,并由FDA批准的Rubra辅助诊断选择进行治疗。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- Near-Term Headwinds Send Nike To The Bargain Basement
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- Is the Bond Market Signaling a Market Bottom?
- 免费获取StockNews.com关于克洛维斯肿瘤学(CLVS)的研究报告
- 近期的逆风将耐克送到了廉价地下室
- 阿彻·丹尼尔斯·米德兰:49年增长的红利英雄
- 全自动拖拉机会让迪尔成为农业领域的特斯拉吗?
- 麦格纳国际是您的汽车和电动汽车一站式库存
- 债券市场是否发出了市场触底的信号?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受Clovis肿瘤学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Clovis Oncology和相关公司的最新新闻和分析师评级的每日简要摘要。